Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mangalam Drugs & Organics's Debt-to-EBITDA or its related term are showing as below:
NSE:MANGALAM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.46 Med: 2.21 Max: 7.77
Current: -7.46
During the past 13 years, the highest Debt-to-EBITDA Ratio of Mangalam Drugs & Organics was 7.77. The lowest was -7.46. And the median was 2.21.
NSE:MANGALAM's Debt-to-EBITDA is ranked worse than 100% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs NSE:MANGALAM: -7.46
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mangalam Drugs & Organics Debt-to-EBITDA Related Terms
Mangalam Drugs & Organics Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangalam Drugs & Organics Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mangalam Drugs & Organics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Mangalam Drugs & Organics (NSE:MANGALAM) has a Debt-to-EBITDA of -4.77 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mangalam Drugs & Organics. According to the industry distribution chart, Mangalam Drugs & Organics ranks #999999 out of 691 companies in the Drug Manufacturers industry.
Is Mangalam Drugs & Organics' Debt-to-EBITDA too high?
Mangalam Drugs & Organics' current Debt-to-EBITDA is -4.77. Based on the distribution chart, Mangalam Drugs & Organics ranks #999999 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mangalam Drugs & Organics has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mangalam Drugs & Organics ranks #999999 out of 691 companies for Debt-to-EBITDA. This places Mangalam Drugs & Organics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mangalam Drugs & Organics. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangalam Drugs & Organics's current Debt-to-EBITDA is -4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹62.32, compared to a current price of ₹27.11 — trading 56.5% below its estimated fair value. The current Debt-to-EBITDA is -4.77. Mangalam Drugs & Organics' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Debt-to-EBITDA is -4.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹27.11 is trading 56.5% below its estimated GF Value™ of ₹62.32.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
Debt-to-EBITDA: -4.77
GF Value™: ₹62.32 vs. price of ₹27.11 (56.5% below fair value)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
38GF Score
Get the complete analysis for NSE:MANGALAM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
